2002). Previous studies have demonstrated that antibodies against TNF-α and IFN-γ could attenuate Con A-induced liver injury (Gantner et al. 1995). Our lab-based studies have suggested that SPRC exerts an anti-inflammatory effect on cardiovascular diseases, neurodegenerative diseases, and vascular endothelium-related diseases by suppressing the release of inflammatory cytokines and modulating the NF-κB pathway (Gong, Pan, et al. 2011; Gong, Wang, et al. 2011; Pan et al. 2011, 2012). Here, SPRR3 is linked to cardiovascular disorder.